Literature DB >> 20671544

Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness.

Joseph A C Delaney1, Rebecca Scherzer, Mary L Biggs, Michael G Shliplak, Joseph F Polak, Judith S Currier, Richard A Kronmal, Christine Wanke, Peter Bacchetti, Daniel O'leary, Phyllis C Tien, Carl Grunfeld.   

Abstract

BACKGROUND: Previous research has demonstrated an increase in carotid intima-media thickness (cIMT) in HIV-infected individuals compared to controls. However, the reason for this increased level of subclinical vascular disease is unknown.
OBJECTIVE: To identify HIV-related risk factors for increased cIMT.
METHODS: We evaluated the relationship between HIV-related characteristics (including markers of HIV disease severity and use of antiretroviral therapy) and cIMT measurements in the internal/bulb and common carotid regions among 538 HIV-infected participants from the Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). We used Bayesian model averaging to estimate the posterior probability of candidate HIV and non-HIV-related risk factors being true predictors of increased cIMT. Variables with a posterior probability of more than 50% were used to develop a selected regression model for each of the anatomic regions.
RESULTS: For common cIMT, the Bayesian model selection process identified age, African-American race, and systolic and diastolic blood pressure with probability more than 95%, HDL cholesterol with probability 85% and Hispanic ethnicity with probability 51%. Among the HIV-related factors included in the analysis, only tenofovir use was selected (51% probability). In the selected model, duration of tenofovir use was associated with lower common cIMT (-0.0094 mm/year of use; 95% confidence interval: -0.0177 to -0.0010). For internal cIMT, no HIV-related risk factors were above the 50% posterior probability threshold.
CONCLUSION: We observed an inverse association between duration of tenofovir use and common carotid cIMT. Whether this association is causal or due to confounding by indication needs further investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20671544      PMCID: PMC3224487          DOI: 10.1097/QAD.0b013e32833d2132

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  34 in total

1.  Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy.

Authors:  M Depairon; S Chessex; P Sudre; N Rodondi; N Doser; J P Chave; W Riesen; P Nicod; R Darioli; A Telenti; V Mooser
Journal:  AIDS       Date:  2001-02-16       Impact factor: 4.177

2.  Tenofovir: a nucleotide analogue reverse-transcriptase inhibitor for treatment of HIV infection.

Authors:  Robert DeChristoforo; Scott R Penzak
Journal:  Am J Health Syst Pharm       Date:  2004-01-01       Impact factor: 2.637

3.  A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.

Authors:  Pierre-Marie Girard; André Cabié; Christian Michelet; Renaud Verdon; Christine Katlama; Patrick Mercié; Laurence Morand-Joubert; Pascal Pétour; Françoise Monchecourt; Geneviève Chêne; Aldo Trylesinski
Journal:  J Antimicrob Chemother       Date:  2009-04-29       Impact factor: 5.790

4.  Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors.

Authors:  Carl Grunfeld; Donald P Kotler; Donna K Arnett; Julian M Falutz; Steven M Haffner; Paul Hruz; Henry Masur; James B Meigs; Kathleen Mulligan; Peter Reiss; Katherine Samaras
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

5.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group.

Authors:  D H O'Leary; J F Polak; R A Kronmal; T A Manolio; G L Burke; S K Wolfson
Journal:  N Engl J Med       Date:  1999-01-07       Impact factor: 91.245

6.  Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors.

Authors:  E Seminari; A Pan; G Voltini; G Carnevale; R Maserati; L Minoli; G Meneghetti; C Tinelli; S Testa
Journal:  Atherosclerosis       Date:  2002-06       Impact factor: 5.162

Review 7.  Mannheim intima-media thickness consensus.

Authors:  P-J Touboul; M G Hennerici; S Meairs; H Adams; P Amarenco; M Desvarieux; S Ebrahim; M Fatar; R Hernandez Hernandez; S Kownator; P Prati; T Rundek; A Taylor; N Bornstein; L Csiba; E Vicaut; K S Woo; F Zannad
Journal:  Cerebrovasc Dis       Date:  2004-11-02       Impact factor: 2.762

8.  B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators.

Authors:  R Li; B B Duncan; P A Metcalf; J R Crouse; A R Sharrett; H A Tyroler; R Barnes; G Heiss
Journal:  Stroke       Date:  1994-12       Impact factor: 7.914

9.  Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study.

Authors:  Carl Grunfeld; Joseph A C Delaney; Christine Wanke; Judith S Currier; Rebecca Scherzer; Mary L Biggs; Phyllis C Tien; Michael G Shlipak; Stephen Sidney; Joseph F Polak; Daniel O'Leary; Peter Bacchetti; Richard A Kronmal
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

10.  The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics.

Authors:  Phyllis C Tien; Constance Benson; Andrew R Zolopa; Stephen Sidney; Dennis Osmond; Carl Grunfeld
Journal:  Am J Epidemiol       Date:  2006-03-08       Impact factor: 4.897

View more
  17 in total

1.  Associations between HIV infection and subclinical coronary atherosclerosis.

Authors:  Wendy S Post; Matthew Budoff; Lawrence Kingsley; Frank J Palella; Mallory D Witt; Xiuhong Li; Richard T George; Todd T Brown; Lisa P Jacobson
Journal:  Ann Intern Med       Date:  2014-04-01       Impact factor: 25.391

2.  Development of a new diabetes risk prediction tool for incident coronary heart disease events: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study.

Authors:  Joseph Yeboah; Raimund Erbel; Joseph Chris Delaney; Robin Nance; Mengye Guo; Alain G Bertoni; Matthew Budoff; Susanne Moebus; Karl-Heinz Jöckel; Gregory L Burke; Nathan D Wong; Nils Lehmann; David M Herrington; Stefan Möhlenkamp; Philip Greenland
Journal:  Atherosclerosis       Date:  2014-08-14       Impact factor: 5.162

3.  Early atherosclerosis in HIV-infected patients below the age of 55 years: Slovenian national study.

Authors:  Mateja Pirs; Barbara Eržen; Mišo Sabović; Primož Karner; Ludvik Vidmar; Mario Poljak; Borut Jug; Mojca Mikac; Janez Tomažič
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

Review 4.  Cardiovascular implications from untreated human immunodeficiency virus infection.

Authors:  Jason V Baker; Jens D Lundgren
Journal:  Eur Heart J       Date:  2011-01-12       Impact factor: 29.983

5.  Markers of atherosclerosis and inflammation and mortality in patients with HIV infection.

Authors:  Alexandra Mangili; Joseph F Polak; Lien A Quach; Jul Gerrior; Christine A Wanke
Journal:  Atherosclerosis       Date:  2010-11-17       Impact factor: 5.162

Review 6.  Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy.

Authors:  Belinda Cruse; Lucette A Cysique; Romesh Markus; Bruce J Brew
Journal:  J Neurovirol       Date:  2012-04-14       Impact factor: 2.643

7.  Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.

Authors:  Petra El Khoury; Mathilde Ghislain; Elise F Villard; Wilfried Le Goff; Caroline Lascoux-Combe; Patrick Yeni; Laurence Meyer; Corinne Vigouroux; Cécile Goujard; Maryse Guerin
Journal:  J Lipid Res       Date:  2015-01-08       Impact factor: 5.922

8.  HIV Infection and Carotid Artery Intima-media Thickness: Pooled Analyses Across 5 Cohorts of the NHLBI HIV-CVD Collaborative.

Authors:  David B Hanna; Mengye Guo; Petra Bůžková; Tracie L Miller; Wendy S Post; James H Stein; Judith S Currier; Richard A Kronmal; Matthew S Freiberg; Siiri N Bennett; Cecilia M Shikuma; Kathryn Anastos; Yanjie Li; Russell P Tracy; Howard N Hodis; Joseph A Delaney; Robert C Kaplan
Journal:  Clin Infect Dis       Date:  2016-04-26       Impact factor: 9.079

Review 9.  Arterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?

Authors:  James H Stein; Judith S Currier; Priscilla Y Hsue
Journal:  JACC Cardiovasc Imaging       Date:  2014-05

10.  Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.

Authors:  Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Akinobu Nakamura; Hideaki Miyoshi; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Koji Yamamoto; Taku Shigesawa; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Journal:  J Gastroenterol       Date:  2020-11-19       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.